Velocardiofacial Syndrome (VCFS) is a genetic disorder that affects about 1 in 4,000 children. It causes medical and developmental issues, and can have a significant impact on the lives of those affected by it. While there is no cure for VCFS, early diagnosis and treatment can help manage symptoms and improve quality of life. This article will provide an overview of VCFS, as well as explain how to diagnose, treat and manage the condition. We'll also discuss how to find support for those living with VCFS.
Velocardiofacial syndrome (VCFS), also known as22q11.2 deletion syndrome, is a condition that results when a tiny piece of chromosome 22 is missing. VCFS is characterized by distinctive facial features, congenital heart defects, cleft palate, and learning disabilities.
The severity of VCFS varies greatly from person to person. Some people with VCFS have only mild symptoms, while others may have more severe problems that require medical intervention. Treatment for VCFS focuses on managing the individual symptoms and may include surgery, speech therapy, and occupational therapy.
There are many possible causes of velocardiofacial syndrome, as it is a complex condition. One theory is that the syndrome is caused by a mutation in a gene called TBX1. This gene is involved in development of the heart, face, and thymus gland. Other possible causes include problems with other genes involved in heart development, or chromosomal abnormalities. The exact cause of velocardiofacial syndrome is often unknown.
Most children with velocardiofacial syndrome have a heart defect. The most common heart defects are:
- A hole in the septum (the wall that separates the two sides of the heart)
- An abnormal connection between the aorta and the pulmonary artery
- A missing pulmonary valve
- A missing or small left ventricle
Some children with velocardiofacial syndrome also have kidney abnormalities. These can include:
- One kidney that is smaller than normal
- Cysts in the kidneys
- Kidney stones
In addition, children with velocardiofacial syndrome often have feeding difficulties and Gastroesophageal reflux disease (GERD). GERD is when stomach contents come back up into the esophagus. This can cause heartburn, vomiting, and difficulty gaining weight.
Treatment
There is no cure for velocardiofacial syndrome, but there are treatments that can help manage the symptoms. Treatment often starts with speech therapy to help improve communication skills. Physical therapy may also be recommended to help with feeding difficulties. In some cases, surgery may be necessary to treat problems with the heart, lungs, or palate.
Medical management of velocardiofacial syndrome often includes close monitoring of heart function and treating any cardiac abnormalities. Children with velocardiofacial syndrome are also at an increased risk for developing psychiatric disorders, so mental health support is often a part of treatment plans as well.
Life expectancy
The average life expectancy for people with velocardiofacial syndrome is about 50 years old. However, many people with the condition live much longer. There is currently no cure for velocardiofacial syndrome, but there are treatments that can help improve symptoms and quality of life.
How common is it?
According to the National Institute of Health, Velocardiofacial syndrome is a rare condition that affects about 1 in 4,000 people.
Conclusion
Velocardiofacial Syndrome is a rare genetic disorder that can have various physical and mental health complications. It is important to understand the full range of symptoms associated with Velocardiofacial Syndrome so you can be adequately prepared for treatment. Fortunately, there are numerous medical treatments available that can help reduce or even eliminate the most common effects of this disease. With proper care and support from family and friends, individuals affected by Velocardiofacial Syndrome can lead fulfilling lives despite their condition.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
In leukemia, allogeneic HCT is beneficial following primary induction failure.
2.
Team finds broken 'brake' on cancer mutation machine.
3.
Omega Fatty Acid Changes Tied to Lower Proliferation Rate in Early Prostate Cancer
4.
Prostate cancer screening program beneficial in top decile of polygenic risk score
5.
Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.
1.
New Research on Craniopharyngioma
2.
What Is May-Hegglin Anomaly? Understanding this Rare Blood Disorder
3.
A Closer Look at White Blood Cells in Urine: Uncovering the Causes and Treatments
4.
The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond
5.
The Mysterious World of Petechiae: Exploring Causes and Treatments
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
4.
Navigating the Complexities of Ph Negative ALL - Part XV
5.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation